Core Insights - Tyra Biosciences is advancing its clinical programs, particularly focusing on dabogratinib for treating conditions like pediatric achondroplasia and bladder cancer, with interim results expected in 2026 [1][2][8] Clinical Development - The company has dosed the first patients in its Phase 2 studies, BEACH301 and SURF302, with expectations for interim results in 2026 [1][2] - Dabogratinib is being expanded into low-grade upper tract urothelial carcinoma (LG-UTUC), where FGFR3 alterations are present in approximately 85% of cases, with an IND cleared by the FDA [1][4][8] - The BEACH301 study is evaluating dabogratinib in children aged 3 to 10 with achondroplasia, while SURF302 focuses on FGFR3-altered low-grade intermediate risk non-muscle invasive bladder cancer [4][10] Financial Overview - As of September 30, 2025, Tyra Biosciences reported cash, cash equivalents, and marketable securities totaling $274.9 million, providing a runway through at least 2027 [1][10] - Research and development expenses for Q3 2025 were $25.5 million, an increase from $22.7 million in Q3 2024, primarily due to start-up and enrollment activities [10][19] - The net loss for Q3 2025 was $29.9 million, compared to $24.0 million for the same period in 2024 [10][19] Pipeline and Future Plans - The company is also developing TYRA-430, an FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, and TYRA-200, an FGFR1/2/3 inhibitor for advanced intrahepatic cholangiocarcinoma [4][12][14] - Upcoming milestones include initial results from the safety sentinel cohort of BEACH301 in 2H 2026 and initial three-month complete response data from SURF302 in 1H 2026 [10][11]

Group 1 - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology [2] - The company utilizes its in-house precision medicine platform, SNÅP, for rapid and precise drug design, predicting genetic alterations that may cause resistance to existing therapies [2] - Tyra's lead product, dabogratinib, is a potential first-in-class selective FGFR3 inhibitor designed to minimize toxicities associated with other FGFR inhibitors [2] Group 2 - Current clinical development plans for dabogratinib include studies for intermediate risk non-muscle invasive bladder cancer, pediatric achondroplasia, and potential future studies for metastatic urothelial cancer [2] - Tyra is also developing TYRA-430, an oral FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, and TYRA-200, an oral FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma [2] - The company will participate in investor events, including a virtual fireside chat on August 21, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [1]